Incretin mimetics close therapeutic gap

Dietary changes and exercise often prove insufficient as measures against morbid obesity. Until now, bariatric surgery has been the only goal-oriented measure for many obese patients. This has changed in the meantime. With incretin mimetics, substantial weight loss can be achieved with parallel improvement in quality of life. While GLP-1-RA mimic the incretin hormone glucagon-like peptide(GLP)-1, dual GIP/GLP-1 agonists also activate glucose-dependent insulinotropic peptide (GIP) receptors.